Aligos Therapeutics, Inc. Common Stock

ALGSNASDAQ • USD
ThemeBiotech - Drug Development›Infectious Disease & Vaccines
7.51 USD
↗ 0.04 (0.54%)AT CLOSE (11:59 AM EDT)
7.82
↗ 0.31 (4.13%)
POST MARKET (AS OF 07:35 PM EDT)
Post Market
AS OF 07:35 PM EDT
7.82
↗ 0.31 (4.13%)
🔴Market: CLOSED

ALGS is currently priced at $7.41. Our models show a "Strong Buy" technical signal alongside a "Neutral" fundamental rating. Notable factors include a concerning Altman Z-Score in the distress zone, negative Return on Equity and a bearish Death Cross on the long-term moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Aug 26, 2026.

Open?$7.37
High?$7.72
Low?$7.04
Prev. Close?$7.47
Volume?68.9K
Avg. Volume?127.5K
VWAP?$7.41
Rel. Volume?0.54x
Bid / Ask
Bid?$5.51 × 100
Ask?$8.90 × 100
Spread?$3.39
Midpoint?$7.21
Valuation & Ratios
Market Cap?46.6M
Shares Out?6.2M
Float?4.8M
Float %?89.2%
P/E Ratio?N/A
P/B Ratio?1.46
EPS?-$12.16
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Themes
Biotech - Drug Development›Infectious Disease & VaccinesBiotech - Drug Development›Metabolic & Cardiometabolic
Employees
82
Market Cap
46.6M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.aligos.com
Listed
2020-10-16
Address
ONE CORPORATE DR., 2ND FLOOR
SOUTH SAN FRANCISCO, CA 94080
Phone: (800) 466-6059
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
0
Momentum?
50
Short Sent.?
71
Piotroski F-Score?4/9Mixed
Altman Z-Score?-16.10Distress
Confidence?50%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?11.81%High
Short Interest?568.1K
Days to Cover?2.7
Free Float4.8M
Avg Daily Volume209.4K
Settlement Date2026-08-14
Financial Health
Current Ratio?2.19Strong
Quick Ratio?2.19Strong
Cash Ratio?1.07Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
88
1.46CHEAP▾
P/S?
Peers
100
S&P
79
1.48CHEAP▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.2CHEAP▾
EV/Sales?
Peers
100
S&P
97
0.52CHEAP▾
Returns & Efficiency
ROE?
S&P
3
-238.2%WEAK▾
ROA?
S&P
3
-114.5%WEAK▾
Cash Flow & Enterprise
FCF?$-94523000
Enterprise Value?$16.3M
Fundamentals ratios updated end of day
MarketsMoversWatchlist